|
STTK | Shattuck Labs, Inc. |
|
|
STTK | Shattuck Labs, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.48 |
| Leverage | 7.07% |
| Market Cap | $ 192.7m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -54.8m |
| Margin | 4379.85% |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is headquartered in Austin, Texas.